Background/Aims: The mechanisms that regulate the size-related morphologies of various blood vessels from the aorta to capillary vessels are still poorly understood. In this study, we evaluate the involvement of regulator of calcineurin 1 (RCAN1), a regulatory protein in the calcineurin/NFAT signal transduction pathway, in vascular morphology to gain further insight into these mechanisms. Methods and Results: We first generated 2 types of vasculature in vitro from the same source of human umbilical vein endothelial cells by fibrin gel assay. We found that RCAN1 was significantly upregulated in large vessels with low branching frequencies when compared with small vessels with high branching frequencies. Next, to clarify whether RCAN1 regulates the branching of blood vessels in vivo, we injected RCAN1 mRNA into fertilized Xenopus laevis eggs. Overexpression of RCAN1 decreased the number of branching points that sprouted from intersomitic vessels during X. laevis angiogenesis. In addition, coexpression of calcineurin A, a target of RCAN1, could rescue RCAN1-suppressed vascular branching. Conclusions: These results provide in vivo evidence of RCAN1-regulated vascular branching which may play a role in the patterning of morphologically different vasculature.

Keywords:
Endothelial cells, Calcineurin, RCAN1, DSCR1, MCIP, Vasculogenesis
1.
Risau W: Mechanisms of angiogenesis. Nature 1997;386:671–674.
2.
Fruttiger M: Development of the retinal vasculature. Angiogenesis 2007;10:77–88.
3.
Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C: VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161:1163–1177.
4.
Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005;169:681–691.
5.
Nakatsu MN, Sainson RC, Aoto JN, Taylor KL, Aitkenhead M, Perez-del-Pulgar S, Carpenter PM, Hughes CC: Angiogenic sprouting and capillary lumen formation modeled by HUVECs in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res 2003;66:102–112.
6.
Sainson RC, Aoto J, Nakatsu MN, Holderfield M, Conn E, Koller E, Hughes CC: Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J 2005;19:1027–1029.
7.
Fuentes JJ, Pritchard MA, Planas AM, Bosch A, Ferrer I, Estivill X: A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Human Mol Genet 1995;4:1935–1944.
8.
Miyazaki T, Kanou Y, Murata Y, Ohmori S, Niwa T, Maeda K, Yamamura H, Seo H: Molecular cloning of a novel thyroid hormone-responsive gene, ZAKI-4, in human skin fibroblasts. J Biol Chem 1996;271:14567–14571.
9.
Yao YG, Duh EJ: VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis? Biochem Biophys Res Commun 2004;321:648–656.
10.
Hesser BA, Liang XH, Camenisch G, Yang S, Lewin DA, Scheller R, Ferrara N, Gerber HP: Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 2004;104:149–158.
11.
Fuentes JJ, Genesca L, Kingsbury TJ, Cunningham KW, Perez-Riba M, Estivill X, de la Luna S: DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum Mol Genet 2000;9:1681–1690.
12.
Fuentes JJ, Pritchard MA, Estivill X: Genomic organization, alternative splicing, and expression patterns of the DSCR1 (Down syndrome candidate region 1) gene. Genomics 1997;44:358–361.
13.
Abe M, Sato Y: cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 2001;4:289–298.
14.
Kingsbury TJ, Cunningham KW: A conserved family of calcineurin regulators. Genes Dev 2000;14:1595–1604.
15.
Flanagan WM, Corthesy B, Bram RJ, Crabtree GR: Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991;352:803–807.
16.
Gorlach J, Fox DS, Cutler NS, Cox GM, Perfect JR, Heitman J: Identification and characterization of a highly conserved calcineurin binding protein, CBP1/calcipressin, in Cryptococcus neoformans. EMBO J 2000;19:3618–3629.
17.
Rothermel BA, Vega RB, Williams RS: The role of modulatory calcineurin-interacting proteins in calcineurin signaling. Trends Cardiovasc Med 2003;13:15–21.
18.
Chang CP, Neilson JR, Bayle JH, Gestwicki JE, Kuo A, Stankunas K, Graef IA, Crabtree GR: A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis. Cell 2004;118:649–663.
19.
Graef IA, Chen F, Chen L, Kuo A, Crabtree GR: Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell 2001;105:863–875.
20.
Iizuka M, Abe M, Shiiba K, Sasaki I, Sato Y: Down syndrome candidate region 1, a downstream target of VEGF, participates in endothelial cell migration and angiogenesis. J Vasc Res 2004;41:334–344.
21.
Minami T, Horiuchi K, Miura M, Abid MR, Takabe W, Noguchi N, Kohro T, Ge X, Aburatani H, Hamakubo T, Kodama T, Aird WC: Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Bboil Chem 2004;279:50537–50554.
22.
Kluetzman KS, Perez AV, Crawford DR: DSCR1 (ADAPT78) lethality: evidence for a protective effect of trisomy 21 genes? Biochem Biophys Res Commun 2005;337:595–601.
23.
Nakatsu MN, Sainson RC, Perez-del-Pulgar S, Aoto JN, Aitkenhead M, Taylor KL, Carpenter PM, Hughes CC: VEGF(121) and vEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest 2003;83:1873–1885.
24.
Hasebe T, Hartman R, Fu L, Amano T, Shi YB: Evidence for a cooperative role of gelatinase A and membrane type-1 matrix metalloproteinase during Xenopus laevis development. Mech Dev 2007;124:11–22.
25.
Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS: Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008;456:814–818.
26.
Nieuwkoop DP, Faber J: Normal Table of Xenopus laevis. Amsterdam, North-Holland, 1994.
27.
Fujiwara M, Jin E, Ghazizadeh M, Kawanami O: Activation of PAR4 induces a distinct actin fiber formation via p38 MAPK in human lung endothelial cells. J Histochem Cytochem 2005;53:1121–1129.
28.
Ryeom S, Baek KH, Rioth MJ, Lynch RC, Zaslavsky A, Birsner A, Yoon SS, McKeon F: Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell 2008;13:420–431.
29.
Ny A, Koch M, Schneider M, Neven E, Tong RT, Maity S, Fischer C, Plaisance S, Lambrechts D, Heligon C, Terclavers S, Ciesiolka M, Kalin R, Man WY, Senn I, Wyns S, Lupu F, Brandli A, Vleminckx K, Collen D, Dewerchin M, Conway EM, Moons L, Jain RK, Carmeliet P: A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med 2005;11:998–1004.
30.
Ciau-Uitz A, Fernandez C, Patient R: Xenopus as a Model to Study Endothelial Development and Modulation. New York, Cambridge University Press, 2007.
31.
Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, Korenberg JR, Folkman J, Daley GQ, Aird WC, Galdzicki Z, Ryeom S: Down’s syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009;459:1126–1130.
32.
Qin L, Zhao D, Liu X, Nagy JA, Hoang MV, Brown LF, Dvorak HF, Zeng H: Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway. Mol Cancer Res 2006;4:811–820.
33.
Gollogly LK, Ryeom SW, Yoon SS: Down syndrome candidate region 1-like 1 (DSCR1-L1) mimics the inhibitory effects of DSCR1 on calcineurin signaling in endothelial cells and inhibits angiogenesis. J Surg Res 2007;142:129–136.
34.
Yang TT, Chow CW: Transcription cooperation by NFAT.C/EBP composite enhancer complex. J Bboil Chem 2003;278:15874–15885.
35.
Macián F, López-Rodríguez C, Rao A: Partners in transcription: NFAT and AP-1. Oncogene 2001;20:2476–2489.
36.
Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN: A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215–228.
37.
Saneyoshi T, Kume S, Natsume T, Mikoshiba K: Molecular cloning and expression profile of Xenopus calcineurin A subunit(1). Biochim Biophys Acta 2000;1499:164–170.
38.
Hashimoto Y, Perrino BA, Soderling TR: Identification of an autoinhibitory domain in calcineurin. J Biol Chem 1990;265:1924–1927.
39.
Fujiwara M, Jin E, Ghazizadeh M, Kawanami O: Differential expression of protease-activated receptors 1, 2, and 4 on human endothelial cells from different vascular sites. Pathobiology 2004;71:52–58.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.